Protocol Ledger

NCT05794139 · Phase II · COMPLETED

Safety and Efficacy of NMD670 in Ambulatory Adult Patients With Type 3 Spinal Muscular Atrophy

Interventional Phase II clinical trial protocol NCT05794139 sponsored by NMD Pharma in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-09-21 Enrollment: 52 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05794139
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)52 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05794139
Protocol FieldVerified Registry Value
NCT IdentifierNCT05794139
Consolidated Lead SponsorNMD Pharma
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment52 participants (ACTUAL)
Registered Start Date2023-09-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI